862 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Here Are the Key Takeaways From J&J's Q1 Earnings Report http://www.zacks.com/stock/news/386860/here-are-the-key-takeaways-from-jjs-q1-earnings-report?cid=CS-ZC-FT-386860 Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
Top Analyst Reports for Wells Fargo, UnitedHealth & Merck http://www.zacks.com/research-daily/382658/top-analyst-reports-for-wells-fargo-unitedhealth-merck?cid=CS-ZC-FT-382658 Apr 17, 2019 - Top Analyst Reports for Wells Fargo, UnitedHealth & Merck
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View http://www.zacks.com/stock/news/382057/jj-jnj-beats-on-q1-earnings-ups-2019-sales-growth-view?cid=CS-ZC-FT-382057 Apr 16, 2019 - J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/381325/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-381325 Apr 16, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Bristol-Myers' Shareholders Vote for Celgene Acquisition http://www.zacks.com/stock/news/381001/bristol-myers-shareholders-vote-for-celgene-acquisition?cid=CS-ZC-FT-381001 Apr 15, 2019 - Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal http://www.zacks.com/stock/news/379777/pharma-stock-roundup-azn-mrk-gsk-get-regulatory-approvals-sandoz-inks-new-deal?cid=CS-ZC-FT-379777 Apr 12, 2019 - Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Intercept Reports Additional Positive Data From NASH Study http://www.zacks.com/stock/news/378691/intercept-reports-additional-positive-data-from-nash-study?cid=CS-ZC-FT-378691 Apr 11, 2019 - Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.
Seattle Genetics' Adcetris Progresses Well Amid Competition http://www.zacks.com/stock/news/379195/seattle-genetics-adcetris-progresses-well-amid-competition?cid=CS-ZC-FT-379195 Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.

Pages: 123456789101112...87

<<<Page 7>